文献速递核素与放射性配体治疗

166Ho微球放射性栓塞治疗挽救性肝转移患者的疗效:一项2期研究

Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study.
PubMed 文献 · J Nucl Med · 2017-09-15

这项前瞻性单臂2期研究纳入56例全身治疗难治且不适合手术切除的肝转移患者,实际治疗38例可评估37例。治疗后3个月目标病灶疾病控制率为73%(95%CI 57%-85%),中位总生存期14.5个月(95%CI 8.6-22.8个月),结直肠癌患者(n=23)中位总生存期13.4个月(95%CI 8.2-15.7个月),3-4级毒性以腹痛(18%)和恶心(8%)为主。作者结论认为166Ho微球放射性栓塞在挽救性肝转移患者中诱导了肿瘤缓解且毒性可接受。

要点

  • 37例可评估患者中27例(73%)在3个月时达到疾病控制(完全缓解、部分缓解或疾病稳定)。
  • 全部患者中位总生存期14.5个月,结直肠癌患者(n=23)中位总生存期13.4个月。
  • 3-4级毒性事件包括腹痛18%、恶心8%,其余事件发生率均为3%。

核心结论

  • 作者结论认为,166Ho微球放射性栓塞在挽救性肝转移患者中诱导了肿瘤缓解且毒性可接受。

研究设计与样本

  • 前瞻性单臂2期研究,共入组56例全身治疗难治且不适合手术切除的肝转移患者,2012年5月至2015年3月间实际治疗38例符合条件患者,其中1例不可评估。
  • 主要终点为治疗后3个月三相肝脏CT上2个目标病灶按RECIST 1.1版评估的缓解;次要终点包括总肿瘤缓解、影像学进展时间、总生存期、毒性、生活质量及SPECT和MRI上微球定量。

主要发现

  • 37例可评估患者中27例(73%)在3个月时目标病灶达到完全缓解、部分缓解或疾病稳定(疾病控制),95%CI为57%-85%。
  • 全部患者中位总生存期为14.5个月(95%CI 8.6-22.8个月)。
  • 结直肠癌患者(n=23)中位总生存期为13.4个月(95%CI 8.2-15.7个月)。
  • 治疗后3-4级毒性事件(按不良事件通用术语标准4.03版)包括腹痛(18%)、恶心(8%)、腹水(3%)、乏力(3%)、胃狭窄(3%)、肝衰竭(3%)、肝脓肿(3%)、阵发性房性心动过速(3%)、胸部疼痛(3%)、上消化道出血(3%)和呕吐(3%)。
  • SPECT上166Ho可被高准确度和精密度定量,肝脏内平均高估9.3%±7.1%。

关键数值与推荐

  • RECIST 1.1版评估的3个月疾病控制率为73%(95%CI 57%-85%),可评估患者37例。
  • 中位总生存期14.5个月(95%CI 8.6-22.8个月),结直肠癌患者(n=23)为13.4个月(95%CI 8.2-15.7个月)。
  • 3-4级毒性事件发生率:腹痛18%、恶心8%,腹水、乏力、胃狭窄、肝衰竭、肝脓肿、阵发性房性心动过速、胸部疼痛、上消化道出血、呕吐各3%。
  • SPECT定量166Ho在肝脏内平均高估9.3%±7.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioembolization of liver malignancies with 166Ho-microspheres has been shown to be safe in a phase 1 dose-escalation study. The purpose of this study was to investigate the efficacy of 166Ho radioembolization. Methods: In this prospective single-arm study, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and ineligible for surgical resection. The primary outcome was a response by 2 target lesions on triphasic liver CT scans 3 mo after therapy, as assessed using RECIST, version 1.1. Secondary outcomes included overall tumor response, time to imaging progression, overall survival, toxicity, quality of life, and quantification of the microspheres on SPECT and MRI. Results: Between May 2012 and March 2015, 38 eligible patients were treated, one of whom was not evaluable. In 27 (73%) of 37 patients, the target lesions showed complete response, partial response, or stable disease (disease control) at 3 mo (95% confidence interval [CI], 57%-85%). The median overall survival was 14.5 mo (95% CI, 8.6-22.8 mo). For colorectal cancer patients (n = 23), the median overall survival was 13.4 mo (95% CI, 8.2-15.7 mo). Grade 3 or 4 toxic events after treatment (according to the Common Terminology Criteria for Adverse Events, version 4.03) included abdominal pain (in 18% of patients), nausea (8%), ascites (3%), fatigue (3%), gastric stenosis (3%), hepatic failure (3%), liver abscesses (3%), paroxysmal atrial tachycardia (3%), thoracic pain (3%), upper gastrointestinal hemorrhage (3%), and vomiting (3%). On SPECT, 166Ho could be quantified with high accuracy and precision, with a mean overestimation of 9.3% ± 7.1% in the liver. Conclusion: Radioembolization with 166Ho-microspheres induced a tumor response with an acceptable toxicity profile in salvage patients with liver metastases.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Prince JF, van den Bosch MAAJ, Nijsen JFW, et al. Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med. 2017. PMID: 28916623. doi:10.2967/jnumed.117.197194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。